Valuation: Intellipharmaceutics International Inc.

Market Cap 1.41M 1.25M 1.17M 1.06M 2M 135M 2.03M 14.13M 5.47M 68.96M 5.28M 5.17M 222M P/E 2021
-0.69x
P/E 2022 -0.82x
Enterprise Value 3.65M 3.24M 3.03M 2.76M 5.2M 351M 5.27M 36.66M 14.19M 179M 13.7M 13.4M 575M EV / Sales 2021
-
EV / Sales 2022 70.4x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.15
5 years 0
Extreme 1.0E-6
0.3
10 years 0
Extreme 1.0E-6
33.5
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 2007-03-31
Corporate Officer/Principal - 2014-01-31
Director TitleAgeSince
Director/Board Member - 2004-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
-0.62%-2.71%+39.30%+114.07% 1,025B
-2.30%-4.44%+39.03%+66.07% 623B
-0.63%-1.96%+6.36%+74.38% 459B
-1.03%-2.82%+59.56%+39.69% 355B
-1.19%-4.52%+21.00%+38.68% 336B
-0.50%-2.07%+12.79%+25.65% 270B
-0.54%-4.73%-3.98%+9.21% 247B
-3.38%+0.30%+36.44%+51.54% 220B
-1.04%-1.46%+32.70%+96.82% 183B
Average -1.12%-1.70%+27.02%+57.35% 371.82B
Weighted average by Cap. -1.17%-2.11%+30.18%+69.28%

Financials

2021 2022
Net sales - 65.73K 58.38K 54.59K 49.75K 93.66K 6.33M 94.95K 660K 256K 3.22M 247K 241K 10.35M
Net income -5.15M -4.57M -4.27M -3.89M -7.33M -495M -7.43M -51.7M -20.01M -252M -19.32M -18.9M -810M -2.89M -2.57M -2.4M -2.19M -4.12M -278M -4.18M -29.06M -11.25M -142M -10.86M -10.62M -456M
Net Debt 1.15M 1.02M 951K 867K 1.63M 110M 1.65M 11.51M 4.46M 56.16M 4.3M 4.21M 180M 2.24M 1.99M 1.86M 1.7M 3.2M 216M 3.24M 22.53M 8.72M 110M 8.42M 8.24M 353M
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. IPCIQ Stock